Analysis suggests that only individuals earning nearly £100,000 annually can make overall savings on food bills after accounting for the £1,200 cost of GLP-1 weight-loss medications, effectively making them a 'regressive tax on being thin'.

Individuals using new weight-loss drugs are reporting a significant change in their relationship with alcohol, with some experiencing a complete loss of cravings or adverse reactions like nausea when drinking.

The daughter of Tim McGraw and Faith Hill has revealed that weight-loss drugs led to the return of her eating disorder. She shared her experience, highlighting the potential risks associated with such medications.

A South Korean biotech company, L&C Bio, is developing an injectable skin booster made from donated human fat to address 'Ozempic face,' the facial volume loss associated with blockbuster weight-loss drugs. This initiative aims to capitalize on the growing demand for cosmetic fixes in the K-beauty market.

Research continues to reveal less-known side effects of GLP-1 weight-loss drugs like Ozempic and Wegovy, beyond common issues like nausea, with new findings highlighting potential impacts on kidney function, hair loss, and menstrual changes.

The effectiveness of natural GLP-1 alternatives to traditional weight-loss drugs is gaining attention, prompting questions about their actual impact and benefits.

Doctors are evaluating weight-loss drugs for an autistic man who has been held in secure care for two decades and is kept in physical restraints.

Reports of side effects such as 'Ozempic face,' hair loss, and digestive problems are increasing as weight-loss medications like Wegovy and Mounjaro gain popularity, prompting research into their robustness.

A weight-loss specialist suggests that GLP-1 drug results can enhance confidence in job interviews and dating, although a study found no clear improvement in overall well-being.

Neurologists are warning that GLP-1 weight-loss drugs like semaglutide (Ozempic, Wegovy) may accelerate the progression of ALS by triggering dangerous rapid weight loss in patients with brain disorders.

An opinion piece and recent reports highlight various negative consequences of using weight-loss injections such as Mounjaro, Wegovy, and Ozempic, including risks like damaged metabolism, muscle loss, and newly identified side effects like 'Ozempic feet'.

The BBC reports on how the increasing use of weight-loss medications is altering consumer spending patterns, with users reporting reduced hunger and changes in purchasing choices for various products.

Scientists at the Endocrine Society congress presented a systematic review of clinical studies, revealing a new groundbreaking effect of weight-loss drugs like Ozempic, Wegovy, and Mounjaro in men, beyond their primary role in weight reduction.

Doctors are issuing warnings about the proliferation of counterfeit weight-loss drugs, often referred to as 'collector peptides' or products mimicking legitimate prescription medications with slight name variations, available for purchase online.

Drugs such as Ozempic, Mounjaro, and Wegovy are showing effects well beyond weight loss and diabetes treatment, NOS

Dutch hospitals and health authorities have issued urgent warnings after two patients fell into comas from injecting counterfeit weight-loss medication purchased online.

The number of reported poisonings from injectable weight-loss drugs in the Netherlands has doubled to 149 cases, raising concerns about more potent variants of these medications.

A new study indicates that GLP-1 drugs, commonly used for weight loss, may also enhance men's fertility by improving reproductive hormones and semen parameters.

A surprising side effect dubbed 'ghost fat' has been observed in patients using injectable weight-loss drugs, raising new considerations for users.

New weight-loss drugs are sparking a revolution in the treatment of overweight and obesity, with discussions about integrated and personalized care pathways becoming widespread across media.

The article highlights three key areas where GLP-1 drugs, used for weight loss and diabetes management, are expected to see significant improvements in the near future.

A global shortage of whey protein is anticipated as the rising popularity of GLP-1 weight-loss drugs fuels increased demand, causing prices to surge fivefold.

Hungarian editor-producer Csilla Tatár spoke in an interview about perimenopause, veganism, and her changed views on weight-loss drugs originally developed for diabetics.

New studies suggest that weight-loss drugs could significantly cut the risk of developing or dying from breast cancer by up to 30%. This adds to evidence of their potential role in cancer prevention.

France is set to begin reimbursing severely obese individuals for the cost of weight-loss drugs, as announced by French Health Minister Stéphanie Rist.

A new discussion explores whether the popularity of weight-loss drugs like Ozempic could pose a significant threat to the business models of hamburger chains.

Several U.S. towns have encountered severe financial difficulties after implementing programs to pay for weight-loss drugs for their teachers and police officers.

A new study indicates that weight-loss medications are continually improving, with another drug demonstrating very high weight loss in a Phase III trial, achieving results comparable to bariatric surgery.

New research suggests that weight-loss drugs may possess an unexpected side effect: the ability to stall the progression of cancer.

The rapid rise of weight-loss drugs is prompting questions and concerns about whether their widespread use could lead to a frailty epidemic.

Danish pharmaceutical giant Novo Nordisk, producer of weight-loss drugs Ozempic and Wegovy, has announced it is abandoning plans to build a new factory in Denmark due to altered global market demand.

Icelandic health authorities are cautioning the public about the sale of weight-loss drugs like Wegovy and Ozempic through unofficial online channels, citing concerns over unknown substances.

New research indicates that the use of GLP-1 weight-loss medications by one individual can encourage healthy habits throughout the entire household.

The U.S. FDA has proposed new restrictions on the mass compounding of weight-loss drugs manufactured by Novo Nordisk and Eli Lilly.

Sales of Magnum's mini ice creams have helped alleviate fears that the rising popularity of weight-loss drugs would negatively impact demand for treats, as Ben & Jerry’s maker beats first-quarter sales forecasts.

The future of obesity treatment is evolving with new weight-loss drugs, including those in pill form, and advancements in personalized therapy. Eli Lilly's CEO projects that these medications could eventually reach about half of potential users at their peak.

A study published in Nature identified a specific genetic variant that may enhance the effectiveness of GLP-1 weight-loss drugs such as semaglutide and tirzepatide.

Several US states are discontinuing Medicaid coverage for GLP-1 weight-loss drugs due to rising demand and costs. This decision comes as dietitians offer advice on how to maintain adequate nutrition while using these medications.

India is examining the potential impact of new weight-loss drugs such as Ozempic and Mounjaro, considering if this marks a significant shift in the country's approach to obesity treatment.

New research indicates that an individual's genetic makeup, specifically variations in two genes linked to appetite and digestion, could be a determining factor in the effectiveness of popular weight loss medications such as Wegovy, Mounjaro, and Ozempic.

The article explores whether a lack of appetite, driven by the increasing use of GLP1 weight-loss drugs, poses a significant threat to the food sector. Currently, 6% of Spaniards use these drugs, with projections indicating a rise to 15-20% in a few years.

New research indicates that individuals with specific variations in genes linked to appetite and digestion may experience greater weight loss when using drugs designed to treat obesity, with DNA helping to determine treatment success.

The CEO of Novo Nordisk stated that the surge in demand for weight-loss medications is just beginning, indicating significant future growth in the market.

A discussion on self-love and body image in the era of weight-loss drugs like Ozempic highlights how social media influences young people, with a mother from Bratislava noting her 12-year-old daughter's appearance concerns after joining Instagram.

Generic versions of popular weight-loss medications like Ozempic and Wegovy are anticipated to become available in Canadian pharmacies this summer, offering more affordable alternatives to patients currently paying $300-$400 monthly for brand-name drugs. This development could significantly impact access and cost for weight management treatments.

Increased access to weight-loss medications has sparked discussions regarding potential concerns and the need for regulatory prudence, while also raising expectations for reduced healthcare spending, particularly in countries like India.

Indian pharmaceutical billionaires are heavily investing in generic weight-loss drugs, a trend that has attracted significant regulatory scrutiny from authorities.

The Health Products Regulatory Authority (HPRA) reported a 'substantial' increase in fake or illegal weight-loss drugs seized last year, with the number of units surging from 1,582 to 48,752.

With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.

Peloton is launching a new strategy for its comeback, targeting users of GLP-1 weight-loss drugs and expanding its treadmill offerings.

The HSE was recently advised that the ‘price of the medicine is too high compared with other ways to manage this condition’.

Despite a significant share price drop, Zealand Pharma's CEO remains optimistic, while Novo Nordisk anticipates competition from cheaper generic versions of its weight-loss drugs entering major markets this year.

An obesity meet in Chennai, India, brought together doctors, nutritionists, and coaches to discuss approaches beyond GLP-1 weight-loss drugs like Ozempic. The event focused on promoting strength training and science-backed diets to combat rising obesity rates and dismantle the stigma around 'celebrity jabs'.

The market for weight-loss drugs is booming - but the pioneer in the field is shedding profits and share value, writes Adam Maguire

Berberine has gained popularity as a 'plant equivalent' to weight-loss drugs like Ozempic. Researchers from Wrocław Medical University are reviewing its efficacy to determine if it's a scientific breakthrough or a myth.

Country star Luke Combs opens up in a Popcast interview about his struggles with body image and explains why he chooses not to use weight-loss drugs, stating he prefers not to take 'the short way'.

The British government is introducing bonuses for general practitioners in England, averaging £3,000, to encourage them to prescribe weight-loss medications as part of an effort to combat rising obesity rates.

A BBC report investigates why some men feel ashamed or perceive using weight-loss injections as 'cheating,' leading to a reluctance to openly discuss their use.

The CEO of Cava, a major restaurant chain, stated that GLP-1 weight-loss drugs are contributing to the emergence of a 'big kids' market, with diners increasingly opting for kids' meals.

Amazon Pharmacy is rolling out cheaper weight-loss drugs, including Ozempic, for as low as $50 a month for Medicare patients, aiming to make treatments more accessible.

Amazon is expanding its healthcare offerings by planning to provide GLP-1 weight-loss drugs to patients covered by Medicare Part D.

A breast cancer surgeon suggests that popular GLP-1 weight-loss drugs like Ozempic and Wegovy may help lower the risk of cancer recurrence by reducing BMI, estrogen levels, and inflammation.

Actor Ethan Suplee, known for 'Remember the Titans,' has issued a warning regarding the growing craze for weight-loss drugs. He shared his concerns about the potential implications of these medications.

A German article discusses the cultural trend of lavish food photography on social media while individuals use weight-loss drugs like Ozempic, questioning if food is now primarily for viewing rather than consumption.

The increasing popularity of GLP-1 weight-loss drugs, such as Ozempic, is significantly altering consumer spending habits and forcing major industries to adapt to these shifts in the economy.

A new study indicates that weight-loss drugs, specifically GLP-1s, could be beneficial for children as young as six years old, potentially also easing pressure on health services.

Startups are currently testing GLP-1 treatments for overweight cats, while major pet-food companies are focusing on longevity products, reflecting a growing trend of owners spending more on animal health.

The financial value of Eli Lilly's weight-loss drugs to investors is being assessed, highlighting their potential impact on the company's market performance.

Users of GLP-1 weight-loss medications in the UK and US are significantly altering their spending habits and wardrobes as they slim down, creating a 'new consumer' trend in clothes shopping.

The increasing use of weight-loss medications is altering consumer behavior, leading to reduced spending on groceries and shifts in purchasing habits across various product categories.

British regulatory bodies have issued a statement reminding pharmacies that public advertising of medical treatments and prescription drugs, including those for obesity and weight management, is prohibited.

Weight-loss drugs like Ozempic and Mounjaro have emerged as Britain's latest cultural divide, replacing Brexit with a fresh wave of judgment, stigma, and shame.

A new study delves into the economics of women's weight, suggesting that weight-loss drugs can help women secure employment and, in some cases, prompt men to leave their partners.

American pharmaceutical giant Eli Lilly is projected to reach nearly $140 billion in revenue by 2032, largely driven by its weight-loss medications. The company's stock market valuation has nearly doubled that of Roche and Novartis combined.

A new study is investigating whether GLP-1 class weight-loss medications, known for appetite suppression, might also influence broader brain functions, including violent behavior.

GLP-1 weight-loss drugs are significantly influencing the bridal industry, leading to increased demand for smaller dress sizes and new waivers. Additionally, these popular medications have been linked to unexpected benefits for male fertility.

Researchers are investigating whether GLP-1 weight-loss drugs could reduce crime rates by improving impulse control and decreasing substance abuse. Initial studies on this potential link have already been conducted.

A new negative effect of GLP-1 based weight-loss medications has reportedly been discovered, which could impact general health.

The increasing use of GLP-1 weight-loss drugs among people in the Black diaspora is prompting discussions about how these medications might reshape perceptions of Black beauty, health, and body image.

A new test helps individuals determine their candidacy for prescription weight-loss drugs like Ozempic, Wegovy, and Mounjaro, which are now available for diabetes and obesity treatment.

Employers are reportedly reducing their coverage for weight-loss medications as the costs associated with these drugs continue to surge.

Bernstein has taken a negative stance on packaged food stocks, citing concerns over persistent inflation and the growing impact of GLP-1 weight-loss drugs on consumer eating habits.

Costco is experiencing a significant increase in sales of protein-packed foods and drinks, driven by a broad demand for added protein, partly fueled by the rising popularity of GLP-1 weight-loss drugs.

Doctors are exploring whether weight-loss drugs like Ozempic can affect emotions and motivation, leading to discussions about a potential 'Ozempic personality'.

Experts suggest that the rapid increase in the use of weight-loss drugs like Wegovy is significantly altering perceptions of attractiveness and beauty standards.

A new report suggests that weight-loss medications produced by pharmaceutical companies Lilly and Novo Nordisk may have an unexpected benefit, showing a link to the stalling of cancer progression.

Toms Group CEO Annette Zeipel discusses how the confectionery industry is adapting to the rise of GLP-1 weight-loss drugs while also contending with volatile cocoa prices.

J.P. Morgan upgraded Cheesecake Factory's stock, citing the restaurant chain's ability to cater to a diverse customer base, including those using weight-loss drugs (GLP-1 users), amidst a cautious consumer environment.

Users of GLP-1 weight-loss drugs are reportedly reducing their restaurant spending, leading to a noticeable impact on the restaurant industry's business performance.

A new trend shows that weight-loss drugs are fueling an increased craving for protein-rich whey products among users.

An advice column addresses a reader's concern about a friend who has become extremely thin due to weight-loss drugs, highlighting worries about her health.

Eli Lilly has raised its profit and sales forecasts, driven by surging demand for its weight-loss drugs, including a new obesity pill. This increased demand is helping to offset pricing pressures and boost the company's financial outlook.

US farmers are increasingly planting peas and lentils, adapting to growing consumer demand for protein-rich foods and the influence of GLP-1 weight-loss drugs on dietary habits.

Rapid weight loss from drugs like Ozempic can have significant consequences for relationships, potentially doubling the divorce risk for married couples as individuals, particularly women, experience empowerment and outgrow their partners.

China is poised to initiate a price war for weight-loss drugs, particularly GLP-1 related treatments like semaglutide, as key patents begin to expire and the country's pharmaceutical industry can produce these treatments at scale.

A new study, based on an analysis of Reddit posts, has found that users of GLP-1 weight-loss medications reported side effects such as fatigue, chills, and menstrual irregularities that were not observed in clinical trials.

Novo Nordisk, maker of Wegovy and Ozempic, is strategizing a comeback in the US market for its weight-loss drugs, aiming to learn from consumer groups to improve its approach.

Eli Lilly is losing market share in India's GLP-1 market due to the influx of cheap semaglutide generics, while Novo Nordisk maintains its position through price cuts for Ozempic and Wegovy.

An overview of the rapidly growing GLP-1 market details the costs of popular weight-loss medications like Wegovy, Zepbound, and Foundayo, and offers advice on choosing the best option.

An operation has been launched against groups involved in the illicit chain of weight-loss products, targeting fraudulent importation, distribution, and irregular commercialization of injectable substances.

The chief of Novo Nordisk estimates that the pharmaceutical industry is currently reaching only a fraction of potential customers for weight-loss drugs, indicating a massive untapped market.

Insurance companies are increasingly cutting off coverage for popular weight-loss medications like Zepbound, leaving patients who have seen significant results without access to their prescriptions.

Amidst the boom in weight-loss medications, a dangerous blind spot has emerged regarding compounding pharmacies, which are reportedly producing unapproved versions of these drugs.

Chinese manufacturers of weight-loss drugs are preparing to compete with global pharmaceutical giants as Novo Nordisk's patent for its popular weight-loss medication expires.

Hims & Hers Health has announced it is now selling Novo Nordisk's popular weight-loss medications, Wegovy and Ozempic, expanding access to these treatments.

India's patent for semaglutide is set to expire on March 20, leading to expectations that approximately 50 branded generic weight-loss drugs will enter the market.

With the introduction of multiple generic variants of GLP-1-weight-loss drugs in the Indian market, concerns have emerged over their on-demand availability.

Model Brooks Nader has revealed her regret over undergoing liposuction, stating she 'forever' regrets it due to unwanted dimples and ripples. She also discussed other cosmetic procedures like fillers and the use of weight-loss drugs to advance her career.

Pharmaceutical company Novo Nordisk is planning to broaden the availability of its weight-loss medications within the Japanese market.

If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.

Restaurant stocks are facing difficulties at the start of 2026, grappling with inflation, inconsistent economic growth, and the widespread use of weight-loss drugs, prompting a search for buying opportunities.

Eli Lilly issued an urgent public warning over compounded weight-loss drugs containing vitamin B12

Companies producing sauces and spices are seeing increased deal interest, as the rise of GLP-1 weight-loss drugs is reportedly leading Americans to seek out more flavorful, 'hot stuff'.

Novo Nordisk to Sell Weight-Loss Drugs Through Hims & Hers  WSJ

Weight-loss drugs may prevent deadly heart complications by opening blocked blood vessels after heart attacks, groundbreaking new research reveals.

New research, based on animal model trials in the UK, suggests that GLP-1 weight-loss drugs could prevent 'no-reflow' complications in heart attack recovery, potentially saving lives.

New research indicates that GLP-1 weight-loss drugs can affect sexual function, with a significant percentage of users reporting changes in their sex lives.

Leading global food and beverage manufacturers, including PepsiCo and Coca-Cola, are set to transform their product portfolios by 2026, focusing on simplifying ingredients in response to the impact of weight-loss medications.

Novo Nordisk announced plans to reduce the U.S. list prices for its popular diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 50%.

Novo's stumbles burnish Lilly's widening lead in weight-loss drugs  Reuters

A Norwegian article outlines five crucial steps for individuals to achieve weight loss without relying on medication, offering an alternative for those who face challenges after discontinuing weight-loss drugs.

The New Zealand dairy industry is experiencing a boom, capitalizing on a surge in global demand for bioactive proteins like whey, which is driven by the increasing popularity of weight-loss drugs such as Wegovy.

The UK's medicines regulator is investigating nearly 200 deaths potentially associated with weight-loss drugs Ozempic and Mounjaro. This comes after reports of over 150 deaths linked to slimming injections.

Medicare's decision to make weight-loss drugs available for $50 a month has ignited a race among pharmacies like Amazon, CVS, and Walmart to fill prescriptions, with Amazon offering significant discounts.

Eli Lilly is teaming up with CVS regarding weight-loss drugs, a development that has generated an LLY stock alert.

Novo Nordisk's chief, Mike Doustdar, emphasized injecting risk-taking into the Ozempic maker, expressing openness to large deals and a strategy to reduce reliance on weight-loss drugs.

Experts warn that the rising trend of 'proteinmaxxing,' where consumers aim to maximize protein intake, combined with increased use of weight-loss drugs, is boosting demand for whey protein. This surge in demand for a key infant formula ingredient could lead to higher prices for baby formula.

While GLP-1 medications are widely used for weight loss, doctors are now exploring their less understood, unexpected impacts on users' romantic relationships and love lives.

An analysis suggests that GLP-1 weight-loss medications like Wegovy and Mounjaro could significantly decrease the risk of alcohol-related hospital admissions by 26%.

Weight-loss drugs and anti-aging treatments are significantly influencing contemporary culture, with new fictional works portraying a society increasingly fearful of fat, aging, and any body type that deviates from perceived norms.

The burgeoning market for weight-loss drugs is identified as a significant investment theme, leading to both substantial gains for some companies and financial challenges for others.

An analysis suggests that while new weight-loss medications offer potential benefits, they are unlikely to fully resolve India's growing obesity crisis, which requires broader public health interventions.

Weight-loss injections are reportedly altering consumer shopping patterns, affecting purchases across a wide range of products from mouthwash to hair dye.

The market for weight-loss drugs is experiencing intense competition as developers line up to tap into this lucrative sector. This increased competition is expected to drive innovation and potentially lower costs for consumers.

An article explores the mechanisms of action for popular weight-loss drugs like Ozempic and Mounjaro, also detailing what happens when individuals stop taking them.

MP Layla Moran has expressed low confidence in the MHRA's ability to combat the black market for counterfeit weight-loss drugs in the UK.

A new Medicare GLP-1 Bridge program, effective July 1, will reduce the cost of weight-loss drugs like Wegovy and Zepbound to $50 a month for eligible seniors.

Reports of people being poisoned by injectable weight-loss drugs nearly doubled in the Netherlands last year, prompting warnings from toxicologists.

UPS plans to invest $48 million in new temperature-controlled facilities to accommodate the growing demand for shipping weight-loss drugs and other healthcare products. This investment reflects a boom in the healthcare logistics sector.

GLP-1 weight-loss drugs like Ozempic are reportedly linked to various cosmetic concerns, including sagging earlobes, deflated breasts, and flatter buttocks, according to surgeons.

The U.S. Food and Drug Administration has sent 25 letters to telehealth companies, cautioning them about claims made regarding compounded weight-loss drugs.

New weight-loss drugs have seen global success, but many patients regain significant weight after discontinuing treatment. Pharmaceutical companies are now working on developing long-term solutions to help users maintain their results.

New research indicates that users of GLP-1 weight-loss drugs are saving over £400 a year on grocery bills, primarily by purchasing fewer snacks and treats like crisps and chocolate, as the drugs' take-up has tripled.

Pfizer has released new data on its experimental weight-loss shot and outlined a strategy to become a leader in the competitive weight-loss drug market, aiming to power its growth in the coming decade.

New research indicates that taking weight-loss medications for at least three years could significantly reduce the need for knee replacement surgeries, potentially preventing thousands of procedures annually for patients with knee arthritis.

Authorities seized 12,000 doses of unlicensed weight-loss medicines during a raid on a country estate near Northampton, leading to the arrest of two men.

Novo Nordisk, the manufacturer of Ozempic, is facing suspicions in Estonia over a campaign that directs people to private clinics discussing weight-loss drugs, which authorities believe might constitute illegal advertising for prescription medications.

Eli Lilly has reported positive Phase 3 clinical trial results for its investigational obesity treatment, Retatrutide, with its latest GLP-1 drug showing significant promise as a powerful weapon in the fight against obesity.

New weight-loss medications are showing promising results in the fight against obesity, but they are also generating excessive enthusiasm, prompting a debate on whether they represent a medical revolution or an illusionary solution.

New research indicates that individuals exhibit diverse responses to GLP-1 drugs like Wegovy, with some being "super-responders" while others show no effect.

Scientists at the Chinese University of Hong Kong are investigating the potential of popular GLP-1 weight-loss injections to aid patients recovering from severe strokes, particularly when used in conjunction with surgical procedures to remove blood clots.

Weight-loss medications like Ozempic can lead to a phenomenon dubbed "Ozempic butt," referring to a specific side effect. The article explains what this condition entails and its connection to the use of such drugs.

The Customs Administration in North Macedonia arrested the owner of a beauty salon and two other individuals for smuggling medical preparations, uncovering a criminal scheme at the Tabanovce border crossing where 535 vials of weight-loss drugs and 7,400 labels were found.

Plus-size model Ashley Graham voiced her concern about the growing popularity of GLP-1 weight-loss drugs and the re-emergence of thinness as a beauty ideal, calling the trend 'discouraging' for the body positivity movement.

The accounting firm PwC is removing coverage for weight-loss medications from its employee health plans, citing the high cost of what it describes as a 'cultural phenomenon'.

The U.S. Food and Drug Administration has proposed removing certain weight-loss drugs from the list of medications that can be compounded, potentially impacting their availability.

Polish scientists have found that popular weight-loss medications, such as Ozempic, may lead to serious nutritional deficiencies, with patients consuming as little as 753 kcal daily.

Amazon.com is set to offer a new program focused on GLP-1 weight-loss drugs, according to the Wall Street Journal.

New research suggests that weight-loss medications could be effective in treating a form of fatty liver disease. The drugs are believed to work by reducing inflammation, offering a potential new therapeutic avenue.

The family behind Tapito, an iconic LA hot sauce, decided to sell their business due to a surge in demand for hot sauce and other condiments, attributed to the growing use of weight-loss drugs like GLP-1s.

Two industries are reportedly bracing for significant changes in consumer behavior and economic impact due to the rising popularity of weight-loss drugs like Ozempic.

The article discusses various treatments for 'Ozempic face,' a cosmetic side effect associated with weight-loss drugs, suggesting options beyond surgical intervention. Surgeons recommend waiting several months before opting for a permanent solution.

Research suggests that an individual's genetic predisposition can play a role in how effectively weight-loss medications such as Wegovy and Mounjaro work, with some people losing less weight even with medication.

An AIIMS endocrinologist discusses whether generic weight-loss drugs should be classified under Schedule H, requiring a doctor's prescription for sale in India.

Novo and Lilly launched their obesity drugs in India last year. The market is forecast to reach ₹80 billion ($851.79 million) by 2030.

Potato farmers are facing a massive surplus as the widespread use of weight-loss medications reduces food demand, putting millions of pounds of potatoes at risk of spoiling.

New weight-loss drugs are being hailed as a medical revolution, but the article highlights that society’s struggle with body size and beauty is a centuries-old issue.

Scientists are scrutinizing weight-loss drugs like Wegovy, which have revolutionized medicine, to investigate a rare but potential risk of eye damage, as their growing popularity raises new safety questions.

India is poised to enter the semaglutide market with affordable weight-loss drugs, with analysts predicting a potential billion-dollar market if priced and implemented correctly.

The government (presumably India) is increasing its scrutiny of GLP-1 weight-loss drugs amidst growing concerns over their unauthorized sales and distribution.

Prices for weight-loss drugs are decreasing in the US market, prompting questions about whether this trend can be replicated elsewhere.

India could soon get a lot thinner - at least in theory.

When Miracle Weight-Loss Drugs Lose Their Edge  WSJ

The weight loss jabs Ozempic, Mounjaro and Weg­ovy — a type of medicine containing semaglutide — are increasingly being seen as a medical wonder of the age.

Lindt reports that users of weight-loss drugs are consuming more chocolate, not less, challenging common assumptions about dietary changes.

A preliminary study suggests that GLP-1 drugs, typically used for diabetes and weight loss, could significantly reduce the need for migraine medication in individuals suffering from chronic migraines.

Jon Taffer says GLP-1 weight-loss medications are hurting restaurants by reducing how much customers eat and drink, making the industry challenging.

The article discusses whether popular weight-loss drugs like Ozempic and Mounjaro are covered by insurance in the UAE, a growing concern for patients.

Brazilian influencer Larissa da Silva Caetano Anunciacao, known as Larissa Caetano, and her husband were arrested on February 24th on suspicion of illegally selling weight-loss medications via Instagram.

Novo Nordisk announced plans to reduce the U.S. list prices for its popular diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 50%. This move aims to make the medications more affordable for patients.